|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders.
|
Proposal 1. |
Stockholders voted as follows with respect to the election of each of the nominees for director identified in the proxy statement:
|
Nominee
|
For
|
Withhold
|
Broker Non-Votes
|
David W.K. Acheson
|
6,218,403
|
418,685
|
5,983,416
|
David W. Bespalko
|
6,183,939
|
453,149
|
5,983,416
|
Katherine L. Davis
|
4,210,823
|
2,426,265
|
5,983,416
|
Richard L. Eberly
|
5,445,668
|
1,191,420
|
5,983,416
|
John G. Potthoff
|
5,276,667
|
1,360,421
|
5,983,416
|
Proposal 2. |
Stockholders voted as follows with respect to approval of the amendment to the Chembio Diagnostics, Inc. 2019 Omnibus Incentive Plan:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
Approval of amendment to the 2019 Omnibus Incentive Plan
|
4,309,726
|
1,621,024
|
706,336
|
5,983,416
|
Proposal 3. |
Stockholders ratified the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2021, by the following vote:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
Ratification of appointment of Ernst & Young LLP
|
11,781,592
|
359,566
|
479,346
|
—
|
Proposal 4. |
Stockholders approved, on a non-binding advisory basis, the compensation paid to our executive officers in 2020, as disclosed in the 2021 proxy statement, by the following
vote:
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
Advisory vote on 2020 executive compensation
|
5,618,506
|
814,997
|
203,585
|
5,983,416
|
Chembio Diagnostics, Inc.
|
||
Dated: June 25, 2021
|
By:
|
/s/Neil A. Goldman
|
Executive Vice President and Chief Financial Officer
|